Function | Location |
---|---|
iwCLL Registration and Badge Pick-up |
Strathblane Hall, Level 0 |
All YIM and iwCLL Meals and Breaks All Exhibits |
EICC – The Exchange, 150 Morrison St, Edinburgh EH3 8EE, UK Cromdale Hall, Level -2 |
Young Investigator Meeting |
EICC – EICC – The Exchange, 150 Morrison St, Edinburgh EH3 8EE, UK Pentland, Level 3 |
iwCLL Meeting |
EICC – EICC – The Exchange, 150 Morrison St, Edinburgh EH3 8EE, UK Pentland, Level 3 |
iwCLL Welcome Reception |
The Edinburgh Castle Castlehill, Edinburgh EH1 2NG, UK |
* Oral Presentation
** Poster Presentation
Friday, 20 September | ||
---|---|---|
7:30 – 8:00 |
YIM Breakfast Tea & Coffee | |
8:00 – 16:15 |
Young Investigator Meeting | |
19:00 – 21:00 | iwCLL Welcome Reception at the Edinburgh Castle |
Saturday, 21 September | ||
---|---|---|
7:15 | Breakfast Coffee & Tea | |
08:15 | Welcome and Introductions Opening Remarks Peter Hillmen |
|
08:30 | History of CLL Gerald Marti |
|
THEME 1: BIOLOGY AND PATHOPHYSIOLOGY | ||
Session 1: |
The CLL (Epi)genome Chair(s): Christopher Oakes, and Tatjana Stankovic |
|
08:45 | Overview of the CLL Genome Jonathan Strefford |
|
09:05 | The Epigenetic Features of CLL: DNA Methylation Christoph Plass |
|
09:25 |
Insights From Tertiary Structure, Chromatin Modifications, and Nuclear Organization José Ignacio Martín-Subero |
|
09:45 |
*Comprehensive genomic testing for chronic lymphocytic leukaemia patients: WGS, one key to patient stratification (2086) Kate Ridout |
|
09:55 |
*BIRC3 loss accelerates leukemic progression through activation of the non-canonical NF-kB signaling of del(11q) CLL cells (2133) Miguel Quijada-Álamo |
|
10:05 |
**Leukemia specific delivery of miR29b induces epigenetic reprogramming with cell cycle arrest and therapeutic benefit in Chronic Lymphocytic Leukemia (2188) Natarajan Muthusamy |
|
10:10 |
**Cooperation between SF3B1 mutation and ATM deletion in the development of CLL (2194) Lili Wang |
|
10:15 | Morning Break | |
Session 2: |
The CLL (Epi)genome (cont.) Chair(s): Sarka Pospisilova, and Deepa Sampath |
|
10:45 | Keynote Evolution and Mathematical Modelling of Cancer Genomes Gad Getz |
|
11:15 | Functional Implications of Genomic Lesions Catherine Wu |
|
11:35 |
The Impact of Regulatory RNA Molecules Marek Mráz |
|
11:55 | ATM: Pathway, Lesions, and Targeting Tatjana Stankovic |
|
12:15 | *Effect of second-generation BTK inhibitors on the functionality of macrophages and neutrophils from CLL patients. (2088) Mercedes Borge |
|
12:25 | *Pyroptosis as a drugable cell death pathway in Chronic Lymphocytic Leukemia: The other side of inflammation. (2052) Angimar Uriepero |
|
12:35 | **Clinical impact of clonal and subclonal TP53 mutations and deletions in chronic lymphocytic leukemia: an Italian multicenter experience (2130) Riccardo Bomben |
|
12:40 | **Minor-clone TP53 mutations in CLL patients entering first-line treatment: clonal evolution and clinical impact (2136) Jitka Malcikova |
|
12:45 |
Lunch | |
Session 3: | The B-Cell Receptor Chair(s): Andrew Steele, and Jan Burger |
|
13:45 | Role of the B-Cell Receptor in B-Cell Oncogenesis Stefano Casola |
|
14:15 |
Dissecting CLL Immunogenetics and Emerging B-Cell Receptor Stereotypes Kostas Stamatopoulos |
|
14:35 | CLL-Specific Aspects of B-Cell Receptor Signaling Graham Packham |
|
14:55 | *Using signal-omics to fingerprint the impact of antigen engagement and therapy on BCR activation in CLL. (1904) Adam Linley |
|
15:05 | *Functional interplay between the B-cell receptor and NOTCH1 in Chronic Lymphocytic Leukemia and in Richter’s syndrome (2065) Francesca Arruga |
|
15:15 | **Targeting MDSCs in CLL-bearing mice by suppressing the synthesis of secretory IgM via activation of RIDD (1987) Chih-Chi Hu |
|
15:20 | **Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia (2047) Pablo Morande |
|
15:25 | **Distinct Immune Signatures in Chronic Lymphocytic Leukemia and Richter Syndrome (2062) Yucai Wang |
|
15:30 |
Afternoon Break | |
Session 4: | Microenvironment and Models of CLL Chair(s): Christopther Pepper, and Varsha Gandhi |
|
15:55 | Linking the Microenvironment With CLL Models Nicholas Chiorazzi |
|
16:15 |
In Vitro Modelling of the CLL Microenvironment Alan Ramsay |
|
16:35 | Murine and Xenograft Models of CLL Shih-Shih Chen |
|
16:55 | Role of NOTCH1 in CLL and in Richter’s Transformation Silvia Deaglio |
|
17:15 | *Mechanisms of Ibrutinib resistance in the Eµ-TCL-1 mouse model of chronic lymphocytic leukemia (2124) Martina Seiffert |
|
17:25 | *3D-culture of CLL cells in bioreactor identifies the bone marrow as a key regulator of HS1 function in response to Ibrutinib (1932) Cristina Scielzo |
|
17:35 | **Analyzing the mutational landscape of two CLL mouse models overexpressing AID identifies proliferative fraction-associated tumor genes involved in leukemic development and progression (2049) Pablo Morande |
|
17:40 | **Modelling Chronic Lymphocytic Leukemia microenvironment in vitro by exploiting newly-established 3D systems (2006) Francesca Vittoria Sbrana |
|
17:45 | **Chronic lymphocytic leukemia remodels the fibroblastic reticular network that contributes to immunosuppression in the tumor microenvironment (2166) Natalia Couto-Francisco |
|
17:50 | **IL10-producing CD38hi B-regulatory cells drive the immunosuppressive microenvironment in CLL and can be targeted with anti-CD38 immunotherapy (2193) Alak Manna |
|
17:55 | End of day 1 |
Sunday, 22 September | |||
---|---|---|---|
07:00 – 8:00 | Industry Supported Symposium |
||
7:15 | Breakfast Coffee & Tea | ||
THEME 2: INNOVATIONS IN THE ASSESSMENT OF CLL | |||
Session 5: | Innovations in the Assessment of CLL Chair(s): Alessandra Ferrajoli, and Nicole Lamanna |
||
08:15 | Laboratory Assessment of CLL, Including MRD as an End Point Andrew Rawstron |
||
08:35 | Molecular Characterization of CLL Richard Rosenquist Brandell |
||
08:55 | Clinical Assessment of CLL Carol Moreno |
||
09:15 | Critical Assessment and New Development of Prognostic Scoring Systems Barbara Eichhorst |
||
09:35 | *Gene expression signatures predict time-to-progression after front-line chemoimmunotherapy for CLL (1925) Kevin Coombes |
||
09:45 | *Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blind randomized CLL12 trial. (1938) Petra Langerbeins |
||
09:55 | **Undetectable minimal residual disease should be the goal of venetoclax therapy in relapsed and refractory chronic lymphocytic leukaemia (2089) Thomas Lew |
||
10:00 | **Predicting tumor lysis syndrome in venetoclax-treated CLL patients (2008) Anthony Mato |
||
10:05 | Morning Break | ||
THEME 3: THERAPY | |||
Session 6: |
Initial Therapy Chair(s): Steven Coutre, and Adrian Bloor |
||
10:35 | Early Intervention: Can We Justify It and What End Points Should We Consider? Petra Langerbeins |
||
10:55 | Current Initial Treatment of CLL – for Young Patients Florence Cymbalista |
||
11:15 | Current Initial Treatment of CLL – for Elderly Patients Valentin Goede |
||
11:35 | Treatment of CLL from 2019 Onwards: E1912 Trial Tait Shanafelt |
||
11:45 | Treatment of CLL from 2019 Onwards: Alliance Trial Danielle Brander |
||
11:55 | Treatment of CLL from 2019 Onwards: iLLUMINATE Trial Alessandra Tedeschi |
||
12:05 | Treatment of CLL from 2019 Onwards: CLL14 Trial Kirsten Fischer |
||
12:15 | *Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged ≥65 year of age: results with 5 years of follow-up for the RESONATE-2 study (1956) Alessandra Tedeschi |
||
12:25 | *Obinutuzumab and ibrutinib treatment induction followed by a minimal residual disease-driven strategy in chronic lymphocytic leukaemia: long-term results in the ICLL-07 FILO trial (1962) Anne-Sophie Michallet |
||
12:35 | **Obinutuzumab as consolidation after chemo-immunotherapy is highly effective in achieving MRD clearance from bone marrow and peripheral blood resulting in improved Progression-free survival: Results of UK NCRI Phase II/III GALACTIC trial (2121) Talha Munir |
||
12:40 | **Long-term efficacy and safety of maintenance with lenalidomide in patients with chronic lymphocytic leukaemia and a high risk of progression after first-line immunochemotherapy (2017) Moritz Fürstenau |
||
12:45 | Keynote Overview of Clonal Evolution and Genomic Instability in CLL and Implications for Therapy Daniel Landau |
||
13:15 | Lunch | ||
14:00 – 15:25 | iwCLL Symposium |
||
15:25 |
Afternoon Break | ||
Session 7: |
Resistance Mechanisms Chair(s): Bryone Kuss, and Loic Ysebaert |
||
15:45 | Development of Resistance to B-Cell Receptor Inhibition Jennifer Woyach |
||
16:05 | Development of Resistance to BCL2 Inhibition Mary Ann Anderson |
||
16:25 | *Prevalence of BTK and PLCG2 mutations in chronic lymphocytic leukemia patients relapsing on ibrutinib: a European Research Initiative on CLL (ERIC) real-world study (2098) Lesley-Ann Sutton |
||
16:35 | *High surface tumor IgM levels associate with reduced response duration and with BTK bypass during ibrutinib therapy in CLL patients (2195) Giorgia Chiodin |
||
16:45 | **CD8+ T-cell exhaustion induced by leukemic cells mediates progression in Chronic Lymphocytic Leukemia (CLL) (2096) Isabel Jiménez |
||
16:50 |
Binet/Rai Medal Presentation | ||
17:05 |
Poster Session Reception | ||
18:35 |
End of day 2 |
Monday, 23 September | |||
---|---|---|---|
07:00 – 08:00 |
Industry Supported Symposium | ||
7:15 | Breakfast Coffee & Tea | ||
Session 8: |
Therapy of Relapsed/Refractory CLL Chair(s): Jacqueline Barrientos, and Barbara Eichhorst |
||
08:15 | B-Cell Receptor-Inhibitor Therapy in Relapsed/ Refractory Disease Susan O’Brien |
||
08:35 | BCL2-Inhibitor-Based Therapy and MRD in Relapsed/Refractory Disease John Seymour |
||
08:55 | Novel Combinations and MRD in Relapsed/ Refractory Disease Matthew Davids |
||
09:15 | Defining Duration of Therapy: Is There a Role for MRD? Talha Munir |
||
09:35 | *Venetoclax combined with ibrutinib based on a minimal residual disease-guided approach in relapsed/refractory chronic lymphocytic leukemia: results of the IMPROVE study (2068) Lydia Scarfo |
||
09:45 | *Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study (2143) Talha Munir |
||
09:55 | **Biological responses to ibrutinib plus venetoclax in the Bloodwise TAP CLARITYstudy (2163) Andrew Rawstron |
||
10:00 | **Pneumocystis jirovecii pneumonia and invasive fungal infection incidence and institutional prophylaxis practices in CLL patients treated with BTK inhibitors (1941) Christine Ryan |
||
10:05 |
Morning Break | ||
Session 9: |
Novel Strategies in Rel/Refr CLL Chair(s): George Follows, and Adrian Wiestner |
||
10:30 | Evolution of Small Molecule Inhibitors: New vs Old John Byrd |
||
10:50 | Updates on Immune Therapy Strategies, Including CAR T-Cell Therapy and Stem Cell Transplant Katy Rezvani |
||
11:10 | *ASCEND Phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) (2158) Wojciech Jurczak |
||
11:20 | *T cell bispecific antibody combination immunotherapy for chronic lymphocytic leukemia (2063) Despoina Papazoglou |
||
11:30 | **A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy (1943) Danielle Brander |
||
11:35 | **Biology and targeting of mutant p53 in CLL (2172) Janani Ravikrishnan |
||
11:40 | Debate: Future Management of CLL: Is There a Role for Cellular Therapy? Moderator: Anna Schuh David Maloney (CAR T) Johannes Schetelig (SCT) Matt Davids (Novel-Novel) |
||
12:20 |
Lunch | ||
Session 10: |
Real-World Data and Registries Chair(s): Neil Kay, and Eva Kimby |
||
13:00 | CLL Clinical Genomics: Overview of the National Programmes in Sweden, the US, the UK, and France Anna Schuh |
||
13:20 | Geographic Diversity and Management of CLL in South American Patients Carlos Sérgio Chiattone |
||
13:40 | Geographic Diversity and Management of CLL in African Patients Norah Akinola |
||
14:00 | Geographic Diversity and Management of CLL in Indian Patients Abraham Varghese |
||
14:20 | Geographic Diversity and Management of CLL in Chinese Patients Shenmiao Yang |
||
14:40 |
Afternoon Break | ||
Session 11: |
iwCLL UPDATES Chair: Peter Hillmen |
||
15:00 |
Reorganization of the iwCLL Michael Hallek |
||
15:30 | An Update From the European Research Initiative on CLL (ERIC) Paolo Ghia |
||
16:00 | Current Efforts From European and US Real-World Data Christopher Fox (EU) and Anthony Mato (US) |
||
16:30 |
Closing Comments Peter Hillmen |
||
16:45 | Close of Workshop |
– Agenda subject to change
* Oral Presentation
** Poster Presentation
Thank you for your interest in viewing the iwCLL 2019 video presentations.
Please complete the following information below to access the presentations.
* required fields